About the Authors

Lian Shan

Contributed equally to this work with: Lian Shan, Y. Ann Chen

Affiliation Frantz Biomarkers, LLC, Mentor, Ohio, United States of America

Y. Ann Chen

Contributed equally to this work with: Lian Shan, Y. Ann Chen

Affiliation Biostatistics, Moffitt Cancer Center and Research Institute, Tampa, Florida, United States of America

Lorelei Davis

Affiliation Frantz Biomarkers, LLC, Mentor, Ohio, United States of America

Gang Han

Affiliation Biostatistics, Moffitt Cancer Center and Research Institute, Tampa, Florida, United States of America

Weiwei Zhu

Affiliation Biostatistics, Moffitt Cancer Center and Research Institute, Tampa, Florida, United States of America

Ashley D. Molina

Affiliation Epidemiology Center, Morsani College of Medicine, University of South Florida, Tampa, Florida, United States of America

Hector Arango

Affiliation West Coast Gynecologic Oncology, Clearwater, Florida, United States of America

James P. LaPolla

Affiliation Women's Cancer Associates, Gynecologic Oncology, St. Petersburg, Florida, United States of America

Mitchell S. Hoffman

Affiliation Gynecologic Oncology, College of Medicine, University of South Florida, Tampa, Florida, United States of America

Thomas Sellers

Affiliation Cancer Epidemiology, Moffitt Cancer Center and Research Institute, Tampa, Florida, United States of America

Tyler Kirby

Affiliation West Coast Gynecologic Oncology, Clearwater, Florida, United States of America

Santo V. Nicosia

Affiliation Department of Pathology and Cell Biology, College of Medicine, University of South Florida, Tampa, Florida, United States of America

Rebecca Sutphen

Rebecca.Sutphen@epi.usf.edu

Affiliation Epidemiology Center, Morsani College of Medicine, University of South Florida, Tampa, Florida, United States of America

Competing Interests

The authors have read the journal's policy and have the following conflicts: 1) Authors and affiliated institutions hold patents on the phospholipids analyzed for this publication and 2) One or more authors are employed by a commercial company. The following patents were filed as a result of the research performed: Method For Detecting Cancer Using LPA as a Marker, Serial #61/189,495, File Date 08/20/08. Licensed 01/09; Method For Detecting Cancer Using Plasmalogens as Markers, Serial #61/199,565, File Date 11/18/08. Licensed 01/09; Method For Detecting Or Monitoring Cancer Using LPC As A Marker (LPC 14∶0), PCT/US2008/012483, File Date 11/05/08. Licensed 01/09; Lysophosphatidylcholine as a Biomarker of Ovarian Cancer, Patent # US6248553 B1, Filing Date 5/13/05. At the time this research was performed and the manuscript was written two co-authors, Lain Shan and Lorelei Davis, were employed by a commercial company by the name of Frantz Biomarkers, LLC. Frantz Biomarkers, LLC is no longer an operating commercial company. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: RS LS YAC LD GH WZ ADM HA JPL MSH TS TK SVN. Performed the experiments: LS LD YAC GH WZ SVN RS. Analyzed the data: YAC GH WZ SVN RS. Contributed reagents/materials/analysis tools: LS YAC LD GH WZ SVN RS. Wrote the paper: LS YAC LD GH WZ ADM HA JPL MSH TS TK SVN RS.